文献速递胸部肿瘤

如何最佳利用免疫治疗作为晚期/转移性非小细胞肺癌一线治疗

How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2019-01-01

本综述汇总了近期临床试验结果,评估抗PD-1抗体帕博利珠单抗和纳武利尤单抗以及抗PD-L1抗体阿替利珠单抗和度伐利尤单抗作为一线单药及联合化疗、其他免疫治疗和抗血管生成药物的疗效。讨论影响治疗选择的因素,包括患者基线临床和人口学特征、肿瘤组织学以及PD-L1表达和肿瘤突变负荷等生物标志物。免疫治疗已成为大多数晚期NSCLC患者一线治疗的核心组成部分,但个体患者治疗管理仍存重要问题。

要点

  • 抗PD-1/PD-L1抗体是无可靶向基因改变的晚期/转移性NSCLC一线治疗的主要手段。
  • 一线免疫治疗包括单药及联合化疗、其他免疫治疗和抗血管生成药物。
  • 治疗选择需考虑患者基线特征、肿瘤组织学及PD-L1表达和肿瘤突变负荷等生物标志物。

核心结论

  • 免疫治疗已成为大多数晚期NSCLC患者一线治疗的核心组成部分,但个体患者治疗管理仍存重要问题。

研究设计与样本

  • 本综述汇总了评估抗PD-1抗体帕博利珠单抗和纳武利尤单抗以及抗PD-L1抗体阿替利珠单抗和度伐利尤单抗作为一线单药及联合化疗、其他免疫治疗和抗血管生成药物的近期临床试验结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibodies that target programmed death 1 (PD-1) or its ligand [programmed death ligand 1 (PD-L1)] have become a mainstay of first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC) without targetable genetic alterations. In this review, we summarize results from recent clinical trials that have evaluated the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies atezolizumab and durvalumab as first-line treatment as monotherapy and in combination with chemotherapy, other immunotherapies, and antiangiogenesis agents. We discuss factors that may influence treatment selection, including patient baseline clinical and demographic characteristics, tumor histology, and biomarkers such as PD-L1 expression and tumor mutation burden. While immunotherapy has become a central component of first-line treatment of most patients with advanced NSCLC, important questions remain about how treatment should be managed for individual patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Peters S, Reck M, Smit EF, et al. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Ann Oncol. 2019. PMID: 30912805. doi:10.1093/annonc/mdz109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。